Cytokinetics reports Q4 2023 net loss of $1.38/share; positive SEQUOIA-HCM results, NDA planned for Q3 2024

CYTOKINETICS INC

2023-FY EPS reported -$5.45 revenue$7,530,000

Net loss Q4 2023: $136.9M ($1.38/share); full year net loss $526.2M ($5.45/share).
Year-end cash $655.4M; additional ~$83M raised via ATM in early 2024; ~2-year cash runway.
SEQUOIA-HCM showed aficamten improved pVO2 by 1.74 mL/kg/min (p=0.000002) vs placebo; all 10 secondary endpoints met.
Plans to submit NDA to FDA in Q3 2024 and MAA to EMA in Q4 2024 for aficamten.
2024 guidance: revenue $3-5M, operating expenses $420-450M, net cash utilization ~$390-420M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CYTOKINETICS INC reported the fourth quarter and full year 2023 results: net income Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill.

Period: the fourth quarter and full year 2023
Net income: Net loss for the fourth quarter was $136.9 million or $1.38 per share and the net loss for the year 2023 was $526.2 mill
Result: reported results

Exact text from the filing

On February 27, 2024, Cytokinetics, Incorporated announced its financial results for the fourth quarter and for the year ended December 31, 2023.

View on SEC.gov

14 earnings releases filed in the last 30 days. Browse all earnings releases →

CYTOKINETICS INC filing history →

Source: SEC EDGAR

accession 0000950170-24-021099

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.